All In Biotech

Free tool

FAERS Monitor: Sarclisa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761113 or its brand name (Sarclisa, Isatuximab-Irfc). Reports on generic versions are filed under their own applications.

Reports

5,800

Serious

5,382

93% of reports

Hospitalization

2,950

Death reported

767

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia524
  • plasma cell myeloma408
  • pneumonia386
  • thrombocytopenia330
  • covid-19306
  • pyrexia295
  • anaemia284
  • infusion related reaction260
  • diarrhoea251
  • off label use242
  • dyspnoea210
  • nausea172
  • drug ineffective162
  • death159
  • acute kidney injury157

Reports by year received

View as table
YearReports
20161
20175
201820
201962
2020353
2021680
20221,138
20231,302
2024814
2025718
2026707

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,359 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
plasma cell myelomaSignal40838.334.914,661
infusion related reactionSignal26014.312.73,194
neutropeniaSignal52414.012.96,342
thrombocytopeniaSignal33010.79.72,909
covid-19Signal3066.35.71,378
anaemiaSignal2845.44.81,023
pneumoniaSignal3864.33.9998
acute kidney injurySignal1573.73.2312
pyrexiaSignal2953.12.8422
diarrhoea2511.41.230
dyspnoea2101.31.219
off label use2421.00.90
nausea1720.80.710
death1590.70.627
drug ineffective1620.40.4119

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.